Drug Profile


Alternative Names: 5,6-MeXAA; AS 1404; ASA 404; Dimethylxanthenone acetic acid; DMXAA; NSC-640488; R1564

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Auckland Cancer Society Research Centre
  • Developer Antisoma; Auckland Cancer Society Research Centre; Novartis
  • Class Antineoplastics; Small molecules; Xanthones
  • Mechanism of Action Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Urogenital cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Nov 2010 Discontinued - Phase-II for Prostate cancer in Australia (IV)
  • 11 Nov 2010 Discontinued - Phase-II for Prostate cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top